Role of lymphokine-activated killer cells as mediators of veto and natural suppression.

Fresh bone marrow cells have veto activity but little if any NK activity. By contrast, lymphokine-activated bone marrow cells have potent natural suppressor as well as veto activity, and also have cytolytic activity characteristic of lymphokine-activated killer cells. Veto activity of fresh bone marrow cells is eliminated by 9 Gy irradiation and by depletion of cells expressing Qa-2, but is unaffected by removal of cells expressing Thy-1, Qa-5, Ly-5, or asialo GM1. By contrast, the veto and NS activities of lymphokine-activated bone marrow cells are both abrogated by C lysis depletion of cells expressing Qa-2, Qa-5, Thy-1, asialo GM1, NK1, and Ly-11, but are unaffected by depletion of cells expressing Ly-2. Bone marrow cells depleted of Qa2+ cells fail to generate veto or natural suppressor activity when cultured in Con A-conditioned medium, unlike bone marrow cells depleted of mature NK1.1+ NK cells. Cloned NK cell line F8 is able to mediate both natural suppression and veto. These findings indicate that bone marrow veto and natural suppression are not mediated by T or NK cells present de novo in the bone marrow, but are dependent on proliferating cells that phenotypically resemble pre-NK cells. The progeny of these cells have the phenotype and functional activity of lymphokine-activated killer cells, and are capable of directly mediating both veto and natural suppression.

• Publication year

  1988

• Venue

  Journal of Immunology

• Publication date

  1988-10-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.141.8.2601PMID 3171179
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Induction of natural killer effectors from human thymus with recombinant IL-2.

  1988cited by this paper
• Cloned natural suppressor cells prevent lethal graft-vs-host disease.

  1987cited by this paper
• Lymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen.

  1987cited by this paper
• Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.

  1986cited by this paper
• The selective growth of murine newborn-derived suppressor cells and their probable mode of action.

  1986cited by this paper
• Origin and differentiation of natural killer cells. I. Characteristics of a transplantable NK cell precursor.

  1985cited by this paper
• Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).

  1985cited by this paper
• Cloned cytolytic T cells can suppress primary cytotoxic responses directed against them.

  1984cited by this paper
• In vitro propagation and cloning of murine natural suppressor (NS) cells.

  1984cited by this paper
• Functional heterogeneity in allospecific cytotoxic T lymphocyte clones. I. CTL clones express strong anti-self suppressive activity

  1984cited by this paper
• Naturally Occurring Spleen‐Associated Suppressor Activity of the Newborn Mouse

  1984cited by this paper
• Studies on the mechanism of suppression of primary cytotoxic responses by cloned cytotoxic T lymphocytes.

  1984cited by this paper
• Natural suppressor (NS) cells found in the spleen of neonatal mice and adult mice given total lymphoid irradiation (TLI) express the null surface phenotype.

  1984cited by this paper
• Functional clonal deletion of cytotoxic T-lymphocyte precursors in chimeric thymus produced in vitro from embryonic Anlagen.

  1983cited by this paper
• Human newborns are deficient in natural killer activity

  1982cited by this paper
• Suppression of cell‐mediated lymphocytotoxicity against minor histocompatibility antigens mediated by Lyt‐1+Lyt−2+ T cells of stimulator‐strain origin

  1982cited by this paper
• Suppressor factor produced by neonatal mouse spleen cells.

  1981cited by this paper
• Suppression of the mixed leukocyte response and of graft-vs-host disease by spleen cells following total lymphoid irradiation (TLI).

  1981cited by this paper
• Human fetal thymus and bone marrow contain target cells for natural killer cells

  1981cited by this paper
• An immunological suppressor cell inactivating cytotoxic T-lymphocyte precursor cells recognizing it

  1980cited by this paper
• Functional properties of Ly 11.2 lymphocytes: a role for these cells in leukemia?

  1980cited by this paper
• Cells in bone marrow and in T cell colonies grown from bone marrow can suppress generation of cytotoxic T lymphocytes directed against their self antigens

  1980cited by this paper
• The immunoregulatory role of bone marrow. II. Characterization of a suppressor cell inhibiting the in vitro antibody response.

  1979cited by this paper
• Do Natural Killer Cells Engage in Regulated Reactions Against Self to Ensure Homeostasis?

  1979cited by this paper
• Further studies on suppressor cell activity in the spleen of neonatal mice.

  1979cited by this paper
• Suppressor activity in the spleen of neonatal mice.

  1978cited by this paper

• Toward Safer CD34+ Megadose T-Cell-Depleted Transplants Following Reduced Intensity and Nonmyeloablative Conditioning Regimens

  2018cites this paper
• Biology of Natural Killer Cells

  2008cites this paper
• Efficacy of transient treatment with FK506 in the early phase on cyclophosphamide-induced bone marrow chimerism and transplant tolerance across MHC barriers.

  2006cites this paper
• Opposing influence of age on the growth and colony-forming ability of mouse melanoma B16 and mammary adenocarcinoma: Correlation with natural killer activity

  2005cites this paper
• Cellular immunosuppression in children with acute lymphoblastic leukemia: Effect of consolidation chemotherapy

  2005cites this paper
• Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity.

  2004cites this paper
• Killer cells protect themselves

  2004cites this paper
• It's tough to be old and anemic

  2004cites this paper
• Strategies for the Induction of Allograft Tolerance

  2001cites this paper
• Study of cord blood natural killer cell suppressor activity

  2001cites this paper
• Cardiac Allograft Rejection

  2001cites this paper
• Veto activity of activated bone marrow does not require perforin and Fas ligand.

  2001cites this paper
• Graft-versus-host disease prevention by rapamycin: cellular mechanisms.

  2000cites this paper
• Human dendritic cells express the thrombopoietin receptor, c‐Mpl

  1999cites this paper
• Immunoregulatory role of CD8alpha in the veto effect.

  1999cites this paper
• The molecular mechanisms of veto mediated regulation of alloresponsiveness

  1999cites this paper
• Suppression of alloreactivity with γδ T-cells: relevance to increased γδ T-cells following bone marrow transplantation

  1998cites this paper
• IL-2-activated murine newborn liver NK cells enhance engraftment of hematopoietic stem cells in MHC-mismatched recipients

  1998cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  1998cites this paper
• Sca1(+)/Mac1(+) nitric oxide-producing cells in the spleens of recipients early following bone marrow transplant suppress T cell responses in vitro.

  1998cites this paper
• Suppression of alloreactivity with gamma delta T-cells: relevance to increased gamma delta T-cells following bone marrow transplantation.

  1998cites this paper
• Post-bone marrow transplant use of immunotherapy.

  1997cites this paper
• Chronic myeloid leukemia as an immunological target

  1997cites this paper
• The potential role of NK cells in the separation of graft‐versus‐tumor effects from graft‐versus‐host disease after allogeneic bone marrow transplantation

  1997cites this paper
• Cytotoxic T‐lymphocytes recognizing P‐glycoprotein in murine multidrug‐resistant leukemias

  1997cites this paper
• Regulation of mouse immuno-responses by a natural suppressor cell clone from bone marrow

  1997cites this paper
• Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes.

  1997cites this paper
• Immunotherapy With Interleukin 2 After Bone Marrow Trnsplantation (BMT)

  1997cites this paper
• Natural killer cell recognition of "self" and "non-self" triggering antigens on normal lymphoblasts.

  1996cites this paper
• Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism.

  1996cites this paper
• Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism

  1996cites this paper
• Interleukin-2 in bone marrow transplantation.

  1995cites this paper
• Mechanisms of tolerance to allografts.

  1994cites this paper
• Lymphokine-mediated secretion of a suppressor factor by monocytic cells derived from human adult peripheral blood.

  1994cites this paper
• Veto Cells and the Induction of Transplant Tolerance in Primates

  1994cites this paper
• TGF-beta mediates natural suppressor activity of IL-2-activated lymphocytes.

  1994cites this paper
• In Vivo Treatment with Monoclonal Antibodies Directed Against CD4 and CD8 Antigens in Miniature Swine

  1994cites this paper
• FURTHER STUDIES OF VETO ACTIVITY IN RHESUS MONKEY BONE MARROW IN RELATION TO ALLOGRAFT TOLERANCE AND CHIMERISM

  1994cites this paper
• Veto suppression: the peripheral way of T cell tolerization.

  1993cites this paper
• Natural killer cells and bone marrow transplantation.

  1993cites this paper
• A comparative analysis of the characteristics and function of naturally occurring and drug-induced natural suppressor cells in mice.

  1993cites this paper
• Generation of lymphokine-activated killer cells with veto and natural suppressor activity from patients with leukemias and lymphomas.

  1993cites this paper
• THE MECHANISM OF IL‐2-MEDIATED PROTECTION AGAINST GVHD IN MICE: II. Protection Occurs Independently of NK/LAK Cells1

  1992cites this paper
• Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: implications for use of LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation.

  1992cites this paper
• A fail-safe mechanism for maintaining self-tolerance

  1992cites this paper
• Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: implications for use of LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation

  1992cites this paper
• Tolerance to host minor histocompatibility antigens after allogenic bone marrow transplantation. Specific donor-host unresponsiveness is maintained by peripheral tolerizing cells.

  1992cites this paper
• Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation.

  1992cites this paper
• Generation and characterization of IL-2-activated veto cells.

  1992cites this paper
• Soybean agglutinin–positive natural suppressor cells in mouse bone marrow inhibit interleukin 2 production and utilization in mixed lymphocyte reactions

  1992cites this paper
• Lymphocyte subset reconstitution following human allogeneic bone marrow transplantation: differences between engrafted patients and graft failure patients.

  1991cites this paper
• Maintenance of self tolerance in CD4+ T lymphocytes by antigen presentation on resting B cells--a hypothesis.

  1991cites this paper
• Prevention of In Vivo Alloreactions by Adoptive Immunotherapy with Lymphokine‐Activated Killer Cells

  1991cites this paper
• Programmed cell death of T cells signaled by the T cell receptor and the alpha 3 domain of class I MHC.

  1991cites this paper
• Kidney allograft tolerance in primates without chronic immunosuppression--the role of veto cells.

  1991cites this paper
• SEPARATION OF ALLOSTIMULATORY AND NATURAL SUPPRESSOR/STEM CELL FUNCTIONS OF MURINE BONE MARROW—IMPLICATIONS FOR BONE MARROW TRANSPLANTATION

  1991cites this paper
• Veto cells induce long-term kidney allograft tolerance in primates without chronic immunosuppression.

  1991cites this paper
• Heterogeneity of the lymphokine-activated killer cell phenotype.

  1991cites this paper
• The veto mechanism in transplant tolerance

  1991cites this paper
• In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment

  1990cites this paper
• Enrichment of natural suppressor activity in a wheat germ agglutinin positive hematopoietic progenitor-enriched fraction of monkey bone marrow.

  1990cites this paper
• Regulation of the cytotoxic T lymphocyte response against Qa-1 alloantigens.

  1990cites this paper
• Inhibition of tumor cell proliferation by natural suppressor cells present in murine bone marrow.

  1990cites this paper
• LAK cells prevent lethal graft-versus-host disease

  1990cites this paper
• Cytotoxic and proliferative T-cell clones with antidonor reactivity from a patient transplanted for severe combined immunodeficiency disease.

  1990cites this paper
• Natural suppressor cells in spleens of irradiated, bone marrow-reconstituted mice and normal bone marrow: lack of Sca-1 expression and enrichment by depletion of Mac1-positive cells.

  1990cites this paper
• Further characterization of murine bone marrow-derived natural suppressor cells. Potential relationships between NS and NK/LAK activities.

  1990cites this paper
• Autologous tumor-specific cytotoxic T-lymphocytes in a child with neuroblastoma.

  1990cites this paper
• Presence of Host‐Reactive and MHC‐Restricted T Cells in a Transplanted Severe Combined Immunodeficient (SCID) Patient Suggest Positive Selection and Absence of Clonal Deletion

  1990cites this paper
• Interleukin 2 enhancement of veto suppressor cell function in T-cell-depleted bone marrow in vitro and in vivo.

  1990cites this paper
• Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.

  1989cites this paper